Characterization of a small molecule PAI-1 inhibitor, ZK4044

Thrombosis Research

Volumn 115, Issue 4, 2005, Pages 341-350

  Liang, Amy ^a   Wu, Faye ^a   Tran, Kathy ^a   Jones, Steven W ^a   Deng, Gary ^a   Ye, Bin ^a   Zhao, Zhuchun ^a   Snider, R Michael ^a   Dole, William P ^a   Morser, John ^a   Wu, Qingyu ^a  

^a BAYER AG   (Germany)

Author keywords

Antithrombotics; Fibrinolysis; PAI 1; PAI 1 inhibitor; Thrombolysis

Indexed keywords

ANTICOAGULANT AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; ZK 4044;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; DRUG MECHANISM; DRUG POTENCY; GENE MUTATION; HIGH THROUGHPUT SCREENING; IC 50; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; SURFACE PROPERTY;

ANILINE COMPOUNDS; ANIMALS; BENZOIC ACIDS; BLOOD COAGULATION FACTORS; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; SERPINS; SURFACE PLASMON RESONANCE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 19944434102     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.09.021     Document Type: Article

References (51)

1. E.D. Sprengers, and C. Kluft Plasminogen activator inhibitors Blood 69 1987 381 387
2. D.J. Loskutoff, M. Sawdey, and J. Mimuro Type 1 plasminogen activator inhibitor Prog. Hemostasis Thromb. 9 1989 87 115
3. D. Collen, and H.R. Lijnen Basic and clinical aspects of fibrinolysis and thrombolysis Blood 78 1991 3114 3124
4. M. Verstraete The fibrinolytic system: from Petri dishes to genetic engineering Thromb. Haemost. 74 1995 25 35
5. B. Wiman Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease Thromb. Haemost. 74 1995 71 76
6. V. Grimaudo, F. Bachmann, J. Hauert, M.A. Christe, and E.K. Kruithof Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism Thromb. Haemost. 67 1992 397 401
7. M. Levi, H. ten Cate, K.A. Bauer, T. van der Poll, T.S. Edgington, and H.R. Buller Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees J. Clin. Invest. 93 1994 114 120
8. A.F. Suffredini, P.C. Harpel, and J.E. Parrillo Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects [see comments] N. Engl. J. Med. 320 1989 1165 1172
9. M.G. Vervloet, L.G. Thijs, and C.E. Hack Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock Semin. Thromb. Hemost. 24 1998 33 44
10. I. Juhan-Vague, S.G. Thompson, and J. Jespersen Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group Arterioscler. Thromb. 13 1993 1865 1873
11. I. Juhan-Vague, and M.C. Alessi Plasminogen activator inhibitor 1 and atherothrombosis Thromb. Haemost. 70 1993 138 143
12. H.M. Hoffmeister, M. Jur, U. Helber, M. Fischer, W. Heller, and L. Seipel Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris Atherosclerosis 144 1999 151 157
13. A. Hamsten, U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, and C. Landou Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 2 1987 3 9
14. L.A. Erickson, G.J. Fici, J.E. Lund, T.P. Boyle, H.G. Polites, and K.R. Marotti Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 346 1990 74 76
15. M. Eren, C.A. Painter, J.B. Atkinson, P.J. Declerck, and D.E. Vaughan Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1 Circulation 106 2002 491 496
16. P.M. Farrehi, C.K. Ozaki, P. Carmeliet, and W.P. Fay Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice Circulation 97 1998 1002 1008
17. D.T. Eitzman, R.J. Westrick, E.G. Nabel, and D. Ginsburg Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice Blood 95 2000 577 580
18. Y. Zhu, P. Carmeliet, and W.P. Fay Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance Circulation 99 1999 3050 3055
19. P. Carmeliet, J.M. Stassen, L. Schoonjans, B. Ream, J.J. van den Oord, and M. De Mol Plasminogen activator inhibitor-1 gene-deficient mice: II. Effects on hemostasis, thrombosis, and thrombolysis J. Clin. Invest. 92 1993 2756 2760
20. T. Abrahamsson, V. Nerme, M. Stromqvist, B. Akerblom, A. Legnehed, and K. Pettersson Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin Thromb. Haemost. 75 1996 118 126
21. J.J. van Giezen, G. Wahlund, V. Nerme, and T. Abrahamsson The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis Thromb. Haemost. 77 1997 964 969
22. M. Levi, B.J. Biemond, A.J. van Zonneveld, J.W. ten Cate, and H. Pannekoek Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis [see comments] Circulation 85 1992 305 312
23. B.J. Biemond, M. Levi, R. Coronel, M.J. Janse, J.W. ten Cate, and H. Pannekoek Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody Circulation 91 1995 1175 1181
24. H.R. Lijnen, L. Moons, V. Beelen, P. Carmelie, and D. Collen Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice Thromb. Haemost. 74 1995 1126 1131
25. Q. Wu, and Z. Zhao Inhibition of PAI-1: a new anti-thrombotic approach Curr. Drug Targets Cardiovasc. Haematol. Disord. 2 2002 27 42
26. B. Ye, S. Bauer, B.O. Buckman, A. Ghannam, B.D. Griedel, and S.K. Khim Synthesis and biological evaluation of menthol-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) Bioorg. Med. Chem. Lett. 13 2003 3361 3365
27. D.P. Beebe, and D.L. Aronson An automated fibrinolytic assay performed in microtiter plates Thromb. Res. 47 1987 123 128
28. L. Zhao, B. Buckman, M. Seto, J. Morser, and M. Nagashima Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity J. Biol. Chem. 278 2003 32359 32366
29. P. Bjorquist, M. Brohlin, J. Ehnebom, M. Ericsson, C. Kristiansen, and G. Pohl Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator Biochim. Biophys. Acta 1209 1994 191 202
30. D.A. Lawrence, S. Palaniappan, S. Stefansson, S.T. Olson, A.M. Francis-Chmura, and J.D. Shore Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis J. Biol. Chem. 272 1997 7676 7680
31. T.H. Ngo, Y. Zhou, J.M. Stassen, and P.J. Declerck Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition Thromb. Haemost. 88 2002 288 293
32. D.A. Lawrence, S.T. Olson, S. Palaniappan, and D. Ginsburg Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition J. Biol. Chem. 269 1994 27657 27662
33. M.B. Berkenpas, D.A. Lawrence, and D. Ginsburg Molecular evolution of plasminogen activator inhibitor-1 functional stability EMBO J. 14 1995 2969 2977
34. S. Fujii, H. Sawa, and B.E. Sobel Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil Thromb. Haemost. 70 1993 642 647
35. M. Kockx, H.M. Princen, and T. Kooistra Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes-role of the peroxisome proliferator-activated receptor-alpha Thromb. Haemost. 80 1998 942 948
36. B. Vinogradsky, S.P. Bell, J. Woodcock-Mitchell, A. Ohtani, and S. Fujii A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits Thromb. Res. 85 1997 305 314
37. W. Zhang, J. Wojta, and B.R. Binder Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells Arterioscler. Thromb. 14 1994 1040 1046
38. W.J. Zhang, J. Wojta, and B.R. Binder Notoginsenoside R1 counteracts endotoxininduced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo Arterioscler. Thromb. Vasc. Biol. 17 1997 465 474
39. P.A. Charlton, R.W. Faint, F. Bent, J. Bryans, I. Chicarelli-Robinson, and I. Mackie Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity Thromb. Haemost. 75 1996 808 815
40. P. Bjorquist, J. Ehnebom, T. Inghardt, L. Hansson, M. Lindberg, and M. Linschoten Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis Biochemistry 37 1998 1227 1234
41. H. Elokdah, M. Abou-Gharbia, J.K. Hennan, G. McFarlane, C.P. Mugford, and G. Krishnamurthy Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization J. Med. Chem. 47 2004 3491 3494
42. B. Ye, Y.L. Chou, R. Karanjawala, W. Lee, S.F. Lu, and K.J. Shaw Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) Bioorg. Med. Chem. Lett. 14 2004 761 765
43. P. Charlton, R. Faint, C. Barnes, F. Bent, A. Folkes, and D. Templeton XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat Fibrinolysis Proteolysis 11 1997 51 56
44. P.W. Friederich, M. Levi, B.J. Biemond, P. Charlton, D. Templeton, and A.J. van Zonneveld Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits Circulation 96 1997 916 921
45. D.L. Crandall, H. Elokdah, L. Di, J.K. Hennan, N.V. Gorlatova, and D.A. Lawrence Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy J. Thromb. Haemost. 2 2004 1422 1428
46. J. Mottonen, A. Strand, J. Symersky, R.M. Sweet, D.E. Danley, and K.F. Geoghegan Structural basis of latency in plasminogen activator inhibitor-1 Nature 355 1992 270 273
47. K. Aertgeerts, H.L. De Bondt, C. De Ranter, and P.J. Declerck Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1 Proteins 23 1995 118 121
48. A.M. Sharp, P.E. Stein, N.S. Pannu, R.W. Carrell, M.B. Berkenpas, and D. Ginsburg The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion Struct. Fold Des. 7 1999 111 118
49. B. De Taeye, G. Compernolle, M. Dewilde, W. Biesemans, and P.J. Declerck Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties J. Biol. Chem. 278 2003 23899 23905
50. H. Nar, M. Bauer, J.M. Stassen, D. Lang, A. Gils, and P.J. Declerck Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation J. Mol. Biol. 297 2000 683 695
51. Y. Xue, P. Bjorquist, T. Inghardt, M. Linschoten, D. Musil, and L. Sjolin Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide Structure 6 1998 627 636